novaxomx is a joint venture company from curasan AG and Xlife Sciences AG based in Frankfurt am Main, Germany. novaxomx focus is on researching, developing, certifying, producing and marketing disruptive biosurgical therapies for musculoskeletal diseases and tissue regeneration. It’s ambition is to improve the biofunctionality of carriers in regenerative processes by biologizing them with exosomes. With clinically proven products, novaxomx offers an innovative biologization option that targets bone regeneration and can be used even more effectively.